H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $50.00 price target on Dyne Therapeutics (NASDAQ: DYN).

The analyst commented: "We recently engaged with Dyne management focused specifically on the DMD regulatory path ahead and the HARMONIA Phase 3 design (see detailed discussion in the appended PDF). On DMD, the management noted that the approval question might be potentially settled, and the debate has now migrated to commercial execution. Towards that they stressed on the differentiating aspects of z-rostudirsen, the dystrophin data showing broad and consistent uptake across diaphragm, heart, and contractile musculature, evidenced by the FVC and cardiac ejection improvements. The 18% muscle-content-adjusted dystrophin at greater than 12 months, and most importantly, the ActiLiège Next contemporaneous natural history comparison, were cited as the strongest elements of the MDA 2026 package given that most of the past analysis were done with decades old natural history data which missed the current standard of care thereby over-inflating the benefit. We reiterate our Buy and our price target of $50."

For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.

Shares of Dyne Therapeutics closed at $20.02 yesterday.